Evidence map›Paper›PMID 39156600›Full record

ReviewThe World Allergy Organization journal2024

Idiopathic hypereosinophilic syndromes and rare dysimmune conditions associated with hyper-eosinophilia in practice: An innovative multidisciplinary approach.

Marco Caminati, Lucia Federica Carpagnano, Chiara Alberti, Francesco Amaddeo, Riccardo Bixio, Federico Caldart, Lucia De Franceschi, Micol Del Giglio, Giuliana Festi, Simonetta Friso and 15 more

Abstract readReview
In one paragraph

Review in The World Allergy Organization journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Fibrotic chronic eosinophilic pneumonia: from inflammation to fibrosis and therapeutic implications.European respiratory review : an official journal of the European Respiratory Society · 2026
    Review
  3. Article
  4. Article
  5. Hypereosinophilia: clinical and therapeutic approach in 2025.Current opinion in allergy and clinical immunology · 2025
    Review
  6. Benralizumab for acute thromboembolism in hypereosinophilic syndrome: a case report.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2025
    Article
  7. Biologic Agents in Idiopathic Hypereosinophilic Syndrome.Pharmaceuticals (Basel, Switzerland) · 2025
    Article
  8. Review
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Marco CaminatiDepartment of Medicine, University of Verona, Verona, Italy.
Lucia Federica CarpagnanoUniversity of Verona, Verona Italy.
Chiara AlbertiPharmacy Unit, Verona Integrated University Hospital, Verona, Italy.
Francesco AmaddeoUnit of Psychosomatics and Medical Psychology, Verona Integrated University Hospital, and Department of Neurosciences, Biomedicine and Movement, University of Verona, Italy.
Riccardo BixioRheumatology Unit, Verona Integrated University Hospital, Verona, Italy.
Federico CaldartGastroenterology and Digestive Endoscopy Unit, The Pancreas Institute, Verona Integrated University Hospital, Verona, Italy.
Lucia De FranceschiDepartment of Medicine, University of Verona, Verona, Italy.
Micol Del GiglioSection of Dermatology and Venereology, Department of Medicine, University of Verona, Verona, Italy.
Giuliana FestiPulmonology Unit, Verona Integrated University Hospital, Verona Italy.
Simonetta FrisoDepartment of Medicine, University of Verona, Verona, Italy.
Luca FrulloniDepartment of Medicine, University of Verona, Verona, Italy.
Paolo GisondiSection of Dermatology and Venereology, Department of Medicine, University of Verona, Verona, Italy.
Mauro KramperaDepartment of Engineering for Innovation Medicine, Section of Innovation Biomedicine, Hematology Area, University of Verona, Verona, Italy.
Giuseppe LippiSection of Clinical Biochemistry and School of Medicine, University of Verona, Verona, Italy.
Claudio MichelettoPulmonology Unit, Verona Integrated University Hospital, Verona Italy.
Giorgio PiacentiniDepartment of Surgical Sciences, Dentistry, Gynecology and Pediatrics, Pediatric Clinic, University of Verona, Verona, Italy.
Patrick PinterUnit of Otolaryngology, Head and Neck Department, University of Verona, Verona, Italy.
Maurizio RossiniDepartment of Medicine, University of Verona, Verona, Italy.
Michele SchiappoliAllergy Unit and Asthma Center, Verona Integrated University Hospital, Verona, Italy.
Cristina TecchioDepartment of Engineering for Innovation Medicine, Section of Innovation Biomedicine, Hematology Area, University of Verona, Verona, Italy.
Laura TeneroDepartment of Surgical Sciences, Dentistry, Gynecology and Pediatrics, Pediatric Clinic, University of Verona, Verona, Italy.
Elisa TinazziUnit of Internal Medicine B, Verona Integrated University Hospital, Verona Italy.
Gianenrico SennaDepartment of Medicine, University of Verona, Verona, Italy.
Matilde CarlucciHealth Directorate, Verona Integrated University Hospital, Verona, Italy.
Multidisciplinary Group on rare dysimmune conditions with hyper-Eosinophilia (GEos)

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hypereosinophilic syndromes (HES) represent a group of rare dis-immune conditions characterized by blood hyper-eosinophilia and eosinophilic related burden. Especially the idiopathic subtype (I-HES) is particularly difficult to diagnose because of its heterogeneous clinical presentation, the lack of specific findings on physical exam, lab tools, and imaging informative enough to unequivocally confirm the diagnosis and the overlap with other entities, including eosinophilic organ-diseases or systemic dis-immune conditions other than I-HES (from atopy to eosinophilic granulomatosis with polyangiitis [EGPA], the last often extremely difficult to distinguish from HES). Taken together, all the features mentioned above account for an extremely difficult early recognition HES and on-time referral to a specialized centre. The referral itself is challenging due to a not univocal specialist identification, because of the variability of physicians managing HES in different settings (including allergist/clinical immunologist, haematologist, internal medicine doctors, pulmonologist, rheumatologist). Furthermore, the approach in terms of personalized treatment identification and follow-up plan (timing, organ assessment), is poorly standardized. Further translational and clinical research is needed to address the mentioned unmet needs, but on practical grounds increasing the overall clinicians' awareness on HES and implementing healthcare pathways for HES patients represent a roadmap that every clinician might try to realize in his specific setting. The present review aims at providing an overview about the current challenges and unmet needs in the practical approach to HES and rare hypereosinophilic allergo-immunological diseases, including a proposal for an innovative multidisciplinary organizational model.

Indexed as

BenralizumabHESHypereosinophilic syndromeMepolizumabMultidisciplinaryPrecision medicine

Identifiers

PMID39156600
PMCPMC11327453

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.